LifeArc

#AI / data analytics / healthtech / informatics #ALS #Alzheimer's #Axol Bioscience #Biologics #Centessa Pharmaceuticals #Corcept Therapeutics #Denali Therapeutics #Eli Lilly #FDA #Hunter Syndrome #LifeArc #Mergers and acquisitions #MND #Ovarian cancer #Stanford University

DDW Highlights: 7 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More

#Podcasts

#ALS #Axol Bioscience #LifeArc #MND

Global initiative to tackle gaps in ALS/MND drug discovery 

A global initiative has launched to close the gap in ALS/MND drug discovery.  The ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience announced the launch of ‘Patient induced pluripotent stem cell (iPSC)-based Research to Improve Sporadic ALS Modelling’ (PRISM ALS), a collaborative effort to expand access to high-quality, patient-derived stem… Read More

#News

Bacteria in Petri dishes
#Antibiotics #Antimicrobial resistance (AMR) #Cystic fibrosis #Funding #Glox Therapeutics #LifeArc

Glox awarded share of £3m cystic fibrosis funding

Glox Therapeutics has been awarded a share of the £3 ($3.6) million funding from the Collaborative Discovery Programme (CDP), launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate with funding from LifeArc.   Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development… Read More

#Business & Investment #News

#Cystic fibrosis #Investment #LifeArc #UK

UK cystic fibrosis network to accelerate new therapeutics

LifeArc and Cystic Fibrosis Trust are jointly investing £15 million to establish a network of research hubs that will accelerate the discovery of novel diagnostics and therapeutics for lung infections. The Translational Innovation Hub Network for Lung Health and Infection will consist of four Innovation Hubs,… Read More

#News

#Antimicrobial resistance (AMR) #Cystic fibrosis #Funding #LifeArc #Medicines Discovery Catapult (MDC)

£3m accelerates new drugs for lung infections in cystic fibrosis

The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has announced the first cohort of drug discovery projects to receive its Collaborative Discovery Programme (CDP) funding. The £3 ($3.9) million programme, funded by LifeArc, will support six early-stage novel antimicrobial projects over two years to accelerate new… Read More

#Business & Investment #News

Saline intravenous (iv) drip in a child's hand
#Cancer Research Horizons #Drug discovery #LifeArc #Oncology #Paediatrics

Research consortium to focus on drug discovery for paediatric cancers

With an initial investment of £28 million in resources and funding, LifeArc and Cancer Research UK have launched a new initiative to develop medicines exclusively for children’s and young people’s cancers. C-Further will bring together researchers, clinicians, scientists and industry to provide support, finance and expertise. Read More

#Cancer Research #News

Demyelination of neuron
#Genetics / genomics #King's College London #LifeArc #MND #Motor neuron disease #Partnership

UK research partners team up to accelerate MND drug discovery

UK charity LifeArc has pledged £1.5 million to fund a new two-year collaborative partnership with King’s College London (KCL) to validate a portfolio of human genetic driven therapeutic targets for motor neuron disease (MND). The new partnership, which will involve scientists from both organisations working closely… Read More

#Editor's Choice #News

Herpes virus cells
#Brain cancer #CureSearch #Herpes virus #LifeArc #MD Anderson Cancer Center #Oncology #Paediatrics

Could a modified cold sore virus cure brain cancer?

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The three-year survival rate for children with high-grade gliomas, without further complications, is only… Read More

#Cancer Research #Editor's Choice #News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

Clinical research
#Drug discovery #LifeArc #Rare disease #Research and development

LifeArc’s £40m research centres to boost research into rare diseases

Four new LifeArc Translational Centres for Rare Diseases have been created to give people living with rare medical conditions access to improved tests and treatments. The virtual centres will focus on areas where there are significant unmet needs. They aim to tackle barriers that ordinarily prevent… Read More

#News

Demyelination of neuron
#ALS #Drug repurposing #LifeArc #Medicines Discovery Catapult #MND Association #Motor neurone disease #Neuroscience

New guiding principles to overcome barriers to MND drug discovery

New guidance for the motor neuron disease (MND) drug discovery community has been published to ensure that future drug discovery and development efforts have the best chance of successfully translating from the lab to the clinic. The whitepaper ‘Guiding principles for drug discovery and development in… Read More

#News #Trending News

Antibodies
#Antibodies #Collaboration #Funding #Infectious diseases #LifeArc #Liverpool School of Tropical Medicine

Infectious diseases research fund will progress antibody therapies

Liverpool School of Tropical Medicine (LSTM) and LifeArc are partnering to launch a new Translational Development Fund to help tackle infectious diseases. LifeArc will invest £2.7 ($3.4) million into the fund, which will support the progression of new technologies and treatments for emerging viral threats and… Read More

#News

Neurons
#ALS #LifeArc #MND #Motor neurone disease #University of Edinburgh

Project to test drug combinations for motor neuron disease

A new project by researchers in Edinburgh aims to identify combinations of existing drugs that could be used together to treat motor neuron disease (MND). Led by Prof Siddharthan Chandran, the £3.3 million project is funded by the medical research charity LifeArc, as part of an… Read More

#News

#ALS #LifeArc #Neuroscience #Partnership #Precision medicine #PrecisionLife

Partners to advance precision medicines for MND

Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease. The collaboration will accelerate… Read More

#News

Bacteria in Petri dishes
#Antibiotics #Antibodies #Antimicrobial resistance (AMR) #Antimicrobials #Cystic fibrosis #Funding #LifeArc

£3m drug discovery programme for cystic fibrosis

UK-based Cystic fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) has announced a £3 million ($3.6 million) Collaborative Discovery Programme for drug discovery innovators to accelerate the development of new treatments for people with CF. Funded by UK medical research charity LifeArc, the programme will support approximately… Read More

#News